Aravax is a clinical stage biotechnology company developing a novel peptide-based immunotherapy, PVX108, for the treatment of peanut allergy. Aravax is striving to improve the lives of patients living with peanut allergies by developing a therapy that precisely targets the underlying cause of diseas...See more
Headquarter Australia |
Countries of operation Australia |
Funding status Series B |
Company type SME |
CFO
Director Clinical Operations
Non Executive Director
Share capital injection/new funding: approx. USD 22,200,000